Radboud Annals of Medical Students

RAMS

  • Home
  • Sign up – Masterclasses 2023!
  • News
    • Newsletter archive
  • About
    • RAMS
    • The Board
    • The General Board
      • The General Board (2022-2023)
      • Previous General Boards
    • The Editorial Board
      • The Editorial Board (2022-2023)
      • Previous Editorial Boards
    • The Supervisory Board
    • Reviewers and Editors
    • RAMS Committees
      • Symposium Committee
      • Masterclass Committee
  • Editions
    • 2021-2022
      • Twentieth Edition – September 2021
      • Twentyfirst Edition – December 2021
      • Twenty second Edition – March 2022
    • 2020-2021
      • Sixteenth edition – September 2020
      • Seventeenth edition – December 2020
      • Eighteenth edition – March 2021
      • Nineteenth Edition – June 2021
    • 2019-2020
      • Fourteenth edition – December 2019
      • Fifteenth edition – April 2020
      • Sixteenth edition – September 2020
    • 2018-2019
      • Eleventh Edition – September 2018
      • Twelfth Edition – January 2019
      • Thirteenth edition – May 2019
    • 2017 – 2018
      • Ninth Edition – November 2017
      • Tenth Edition – February 2018
    • 2016-2017
      • Sixth Edition – November 2016
      • Seventh Edition – March 2017
      • Eighth Edition – July 2017
    • 2015-2016
      • Third Edition – November 2015
      • Fourth Edition – March 2016
      • Fifth Edition – June 2016
    • 2014-2015
      • Pilot Edition – June 2014
      • First Edition – January 2015
      • Second Edition – June 2015
  • For Authors
    • Submit your Article
    • Research internship
  • For Supervisors
  • For Reviewers
  • Contact
  • Privacy policy
  • Cookiebeleid (EU)
Je bent hier: Home / News / Treatment of COVID-19: where are we at the moment?

Treatment of COVID-19: where are we at the moment?

9 juni 2020 by Rams

Quentin Marsman

2020 is the year of COVID-19. The disease caused by the new coronavirus has been a major health concern in the first months of this year and was declared a pandemic by the World Health Organization (WHO) in March [1]. The disease has led to lockdowns in multiple countries as a means to limit the spread of the virus. To touch upon the severity of the disease: on the 26th of May there were over 5.406.282 confirmed cases and 343.562 confirmed deaths [2]. In this brief message, the current perspectives on the treatment of the disease will be explored.

At this moment, no therapy has been officially approved in order to treat COVID-19 patients. Current clinical management consists of infection prevention, control measures, and supportive care [1]. The general public is hoping for life to back to normal as soon as possible. However, for this to happen we need a vaccine.Unfortunately, vaccine development takes a long time and a vaccine is not to be expected to be available before the end of the year. This does not mean that we have to just sit and wait for a vaccine. The focus of researchers has partly shifted to the use of existing medicines to quickly find an effective treatment for these patients.

China has started to treat their patients with Favilavir, an antiviral drug, which shows positive effects on the symptoms of COVID-19 [1]. Furthermore, in a recent trial, the antiviral drug Remdesivir was found to shorten the time to recovery [3]. Additionally, chloroquine and hydroxychloroquine, two malaria drugs, have been found to have in vitro activity against the virus [1]. In several countries, such as the United States, these two drugs are recommended for the treatment of COVID-19 patients. The anti-retroviral drug lopinavir/ritonavir was associated with improvement in patients in the 2003 SARS-CoV outbreak, suggesting a possible use against the new coronavirus. Interestingly, the WHO suggests that there may be benefits of these drugs, despite a 99 patient trial showing no benefit compared to standard care [4].

Furthermore, the WHO facilitates an international clinical trial called ‘Solidarity’ to help find a treatment for COVID-19 [5]. Over 400 hospitals in 35 countries are participating in this trial and around 3500 patients have been enrolled in the trial. The goal of the trial is to reduce the time to find a cure by 80 percent as compared to normal [5]. There are four treatment options included in the trial, namely remdesivir, lopinavir/ritonavir, lopinavir/ritonavir with interferon beta-1a, and hydroxychloroquine. No results are available yet.

In the long run, a vaccine will be the most ideal treatment to prevent people from getting the disease. There are several vaccines under development all around the world. First stage clinical trials to assess safety have already started, second stage clinical trials to assess effectiveness will start within around eight months and it is estimated that a vaccine will become available after around 12-18 months [1].

To conclude, no treatment for COVID-19 has been found yet. However, anti-viral drugs and malaria drugs showed promising effects in patients. The ‘Solidarity’-trial facilitated by the WHO researching the before mentioned drugs is a worldwide attempt to find a suitable treatment as soon as possible. Furthermore, multiple countries are also working towards a vaccine but this is not expected to be available soon. It is to be hoped that a cure will be found soon so we can all go back to the lives we once had.

 

References:

[1] Abd El-Aziz, T.M. & Stockand, J.D. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) – an update on the status. Infect Genet Evol 83, 104327-104327 (2020).

[2] World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. (2020). Retrieved from: https://covid19.who.int/ (Accessed: 27-05-2020)

[3] Beigel, J.H., et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. New England Journal of Medicine (2020).

[4] Cao, B., et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine 382, 1787-1799 (2020).

[5] World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. (2020). Retrieved from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments (Accessed: 27-05-2020)

Categorie: News, Uncategorized

RAMS Newsletter

RAMS complies to the GDPR. By submitting your e-mail address to us you agree with our Privacy Policy.

Social Media


Sponsors & Partners

  • Brian Gardner
  • Lauren Mancke
  • Nathan Rice
  • Nick Croft
  • Rafal Tomal
  • Ron Rennick
© Copyright 2014 RADBOUD ANNALS OF MEDICAL STUDENTS · All Rights Reserved · Powered by PLatform11
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Altijd ingeschakeld
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDuurOmschrijving
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
OPSLAAN & ACCEPTEREN
Aangedreven door CookieYes Logo